Pharmaniaga Berhad Balance Sheet Health
Financial Health criteria checks 1/6
Pharmaniaga Berhad has a total shareholder equity of MYR-271.4M and total debt of MYR1.2B, which brings its debt-to-equity ratio to -436.9%. Its total assets and total liabilities are MYR1.9B and MYR2.2B respectively.
Key information
-436.9%
Debt to equity ratio
RM1.19b
Debt
| Interest coverage ratio | n/a |
| Cash | RM127.44m |
| Equity | -RM271.38m |
| Total liabilities | RM2.17b |
| Total assets | RM1.90b |
Recent financial health updates
Recent updates
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate
Apr 19
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price
Oct 03Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?
Jul 19Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?
Feb 18Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital
Dec 10Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts
Nov 24We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings
Aug 27Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet
May 28Financial Position Analysis
Short Term Liabilities: PHARMA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: PHARMA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: PHARMA has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: PHARMA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PHARMA has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if PHARMA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.